Skip to content

Author

S. Fröhling

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma

Anaplastic ependymoma is a rare and aggressive central nervous system malignancy for which effective systemic treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated intracranial activity in patients with HER2-...

D. Krex, I. Kerle, Arne Grey et al. · 1 citation
Open access Oct 2026

Matched primary-metastasis single-nucleus and spatial profiling of leiomyosarcoma identifies antigen-presenting fibroblasts at the tumor-organ interface

Leiomyosarcoma is an aggressive soft tissue sarcoma that metastasizes preferentially to lung and liver. Because matched primary and metastatic specimens are rarely available, the cellular changes that accompany metastatic progression remain poorly defined. Here we combined single-nucleus RNA sequencing of archival FFPE...

Anna Kübler, L. Bergmayr, T. Knösel et al. · 0 citations
Open access Sep 2026

Analytical and Biological Factors Associated with Oncogenic Variant Yield in Tumor-Agnostic Plasma ctDNA Profiling

Background/Objectives: Tumor-agnostic plasma ctDNA profiling is used when tumor tissue is unavailable, insufficient, or unrepresentative. We investigated analytical and biological factors associated with oncogenic variant yield. Methods: In the prospective EXMASTER study, plasma cfDNA was analyzed using a 265-gene targ...

Stephen George, L. Ranganathan, Yi-Zhen Xiang et al. · 0 citations
Preprint Aug 2026

DNA Methylation Profiling in Melanoma: From Lesion Classification to Therapeutic Stratification

It is demonstrated that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.

J. Winterstein, L. Heinlein, G. Raddatz et al. · 0 citations
Open access Aug 2026

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.

N. Kehl, T. Wagner, Simon Steiger et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.